ARTA
TRIB

A.R.T. Advisors’s Trinity Biotech TRIB Stock Holding History

A.R.T. Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,602
Closed -$137K – 1720
2017
Q1 		$137K Buy
4,602
+1,942
+73% +$60.7K 0.01% 1233
2016
Q4 		$92K Buy
+2,660
New +$91.6K 0.01% 1158
2016
Q1 		– Sell
-6,948
Closed -$408K – 1647
2015
Q4 		$408K Buy
+6,948
New +$410K 0.02% 946
2015
Q1 		– Sell
-3,283
Closed -$287K – 1692
2014
Q4 		$287K Buy
3,283
+1,090
+50% +$93.9K 0.01% 1114
2014
Q3 		$200K Buy
+2,193
New +$237K 0.01% 1098

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

A.R.T. Advisors's TRIB Position: Q2 2017 in Review

A.R.T. Advisors sold out of Trinity Biotech (TRIB) in Q2 2017, closing a stake of 4,602 shares — an estimated $137K sold.

A.R.T. Advisors first reported a position in TRIB in Q3 2014 and held it in 5 quarters. The position peaked at $408K in Q4 2015. 56 funds tracked by Wall St. Rank hold TRIB as of Q2 2017.

  • A.R.T. Advisors reported no remaining Trinity Biotech position as of Q2 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 4,602 Trinity Biotech shares in Q2 2017, an estimated $137K.
  • A.R.T. Advisors first reported a position in Trinity Biotech in Q3 2014 and held it in 5 quarters.
  • A.R.T. Advisors's Trinity Biotech position peaked at $408K in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2017.

Based on A.R.T. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.